×
About 775 results

ALLMedicine™ Lipoprotein (a) Center

Research & Reviews  286 results

Association between lipoprotein (a) and heart failure with reduced ejection fraction de...
https://doi.org/10.1002/jcla.24083
Journal of Clinical Laboratory Analysis; Wu B, Zhang Z et. al.

Dec 2nd, 2021 - The current study aimed to evaluate the relationship between baseline serum lipoprotein (a) [Lp(a)] level and heart failure with reduced ejection fraction (HFrEF) development. This was a retrospective study, and participants were enrolled from the...

Colorectal Cancer Detected by Machine Learning Models Using Conventional Laboratory Tes...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606732
Technology in Cancer Research & Treatment; Li H, Lin J et. al.

Nov 23rd, 2021 - Background: Current diagnostic methods for colorectal cancer (CRC) are colonoscopy and sigmoidoscopy, which are invasive and complex procedures with possible complications. This study aimed to determine models for CRC identification that involve m...

Long-Term Prognostic Implications and Role of Further Testing in Adults Aged ≤55 Years ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607758
The American Journal of Cardiology; Cainzos-Achirica M, Acquah I et. al.

Nov 20th, 2021 - The long-term prognostic significance of a coronary artery calcium (CAC) score of 0 is poorly defined in younger adults. We evaluated this among participants aged 45 to 55 years from the Multi-Ethnic Study of Atherosclerosis, and assessed whether ...

A Study of LY3819469 in Healthy Participants
https://clinicaltrials.gov/ct2/show/NCT04914546

Nov 18th, 2021 - This is a 2-part study. In Part A, the main purpose is to evaluate the safety and tolerability of the study drug LY3819469 in healthy participants with high lipoprotein (a) [Lp(a)] levels. How the body processes the study drug and the effect of th...

Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD
https://clinicaltrials.gov/ct2/show/NCT04023552

Nov 17th, 2021 - This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

see more →

Guidelines  1 results

Menopause symptom management in women with dyslipidemias: An EMAS clinical guide.
https://doi.org/10.1016/j.maturitas.2020.03.007
Maturitas Anagnostis P, Bitzer J et. al.

Mar 27th, 2020 - Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile, with an increase in the concentrations of total cholesterol (TC) and low-density lipoprotein choles...

see more →

Clinicaltrials.gov  8 results

A Study of LY3819469 in Healthy Participants
https://clinicaltrials.gov/ct2/show/NCT04914546

Nov 18th, 2021 - This is a 2-part study. In Part A, the main purpose is to evaluate the safety and tolerability of the study drug LY3819469 in healthy participants with high lipoprotein (a) [Lp(a)] levels. How the body processes the study drug and the effect of th...

Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD
https://clinicaltrials.gov/ct2/show/NCT04023552

Nov 17th, 2021 - This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

Thrombophilic Risk Factors in Preterm and Infants Treated at Ha'Emek Medical Center Between the Years 1990 to 2010
https://clinicaltrials.gov/ct2/show/NCT01443273

Nov 1st, 2019 - All the demographic and clinical data will be summarized. Factors non related to the coagulation system like catheters, severe infections or congenital heart defects will be recorded. Also a full workup of prothrombotic risk factors are routinely ...

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)
https://clinicaltrials.gov/ct2/show/NCT02597127

May 17th, 2019 - Participants will be screened and 480 eligible participants will be randomized: 60 participants per each of six ALN-PCSSC dose groups plus 120 participants total across the placebo groups (20 participants each to match each of the six drug dose gr...

Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia
https://clinicaltrials.gov/ct2/show/NCT02462655

Mar 8th, 2016 - Familial hypercholesterolemia (FH) is an autosomal codominant single-gene disorder caused by mutations in the LDL receptor gene that disrupt the normal clearance of LDL particles from the plasma compartment. Heterozygous patients present a 2- to 3...

see more →

News  15 results

2018 AHA/ACC Multisociety Cholesterol Guideline vs 2019 ESC/EAS Dyslipidemia Guidelines: 5 Things to Know
https://www.medscape.com/viewarticle/952765

Jun 30th, 2021 - The 2018 American Heart Association (AHA)/American College of Cardiology (ACC) Multisociety Cholesterol Guideline and the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Guidelines for the Management of Dyslipidaem...

Alirocumab effective in homozygous FH
https://www.mdedge.com/cardiology/article/219835/lipid-disorders/alirocumab-effective-homozygous-fh
Bruce Jancin

Mar 30th, 2020 - Alirocumab achieved a mean 63-mg/dL reduction in LDL cholesterol in the ODYSSEY HoFH study, the largest-ever randomized, placebo-controlled clinical trial of lipid-lowering in adults with homozygous familial hypercholesterolemia (HoFH), Dirk Blom,.

Niacin's effect on cardiovascular risk: Have we finally learned our lesson?
https://www.mdedge.com/ccjm/article/96071/cardiology/niacins-effect-cardiovascular-risk-have-we-finally-learned-our-lesson?channel=194
Stephen J. Nicholls, MBBS, PhD

May 1st, 2014 - Randomized controlled trials have unequivocally shown that lowering levels of low-density lipoprotein cholesterol (LDL-C) with statins reduces the rate of cardiovascular events. 1–3 Yet many patients still have heart attacks even though they are on.

New EAS Consensus Document Tackles Familial Hypercholesterolemia
https://www.medscape.com/viewarticle/805252

Jun 4th, 2013 - LYON, France — The European Atherosclerosis Society (EAS) writing group will soon publish a new consensus document tackling the underdiagnosis and undertreatment of heterozygous familial hypercholesterolemia (FH), said Dr Børge Nordestgaard (Unive...

New EAS Consensus Document Tackles Familial Hypercholesterolemia
https://www.staging.medscape.com/viewarticle/805252

Jun 4th, 2013 - LYON, France — The European Atherosclerosis Society (EAS) writing group will soon publish a new consensus document tackling the underdiagnosis and undertreatment of heterozygous familial hypercholesterolemia (FH), said Dr Børge Nordestgaard (Unive...

see more →